Patient Assistance Programs for Keytruda
Merck offers the KEY+COMPASS program, which provides Keytruda free to eligible uninsured or underinsured U.S. patients with household income up to 800% of the federal poverty level (about $125,000 for a family of four in 2024). It also covers copays up to $25,000 annually for commercially insured patients.[1] Apply via Merck's patient support site or call 1-855-257-3932.
Manufacturer Copay Cards and Discounts
Keytruda's copay savings card reduces out-of-pocket costs to $0 for the first four doses (up to $2,500 per dose), then $950 per dose for eligible commercially insured patients. No income limits apply, but it excludes government insurance like Medicare.[1] Download from Merck's website.
Biosimilar and Generic Alternatives
No true generics exist yet due to Keytruda's (pembrolizumab) biologic status, but biosimilars are emerging. The first U.S. approval came in 2024 for Sandoz's Pembrolizumab-srlf (biosimilar to Keytruda), though launch awaits patent resolutions. European biosimilars like Bioeq's are already available at 25-30% lower prices.[2] Check DrugPatentWatch.com for U.S. patent expiry details—Keytruda's main composition patent ends December 2028, with others extending to 2034 amid challenges.[3]
Lower-Cost Countries and Travel Options
Keytruda lists at $160 per mg in the U.S. (full dose ~$11,000+ monthly), but costs $3,000-$5,000 monthly in Canada, $1,500 in India, or $2,500 in Mexico via medical tourism. Patients travel for infusions, saving 50-80%, but face import risks and insurance denials. Verify via InternationalDrugPriceIndicator.org.[4]
Medicare and Insurance Negotiation Tactics
Medicare Part B covers 80% after deductible; appeals prior authorizations or switch to Medicare Advantage plans with lower copays. Use tools like GoodRx for pharmacy comparisons (though Keytruda is infusion-only) or appeal via patient navigator services. Inflation Reduction Act caps some drug costs starting 2026.[5]
Clinical Trials and Compassionate Use
Join Keytruda trials via ClinicalTrials.gov for free access—over 1,500 active, often in combination therapies for cancers like melanoma or NSCLC. Expanded access programs provide it outside trials for terminal patients.6
[1]: https://www.merckhelps.com/keytruda
[2]: https://www.fda.gov/news-events/press-announcements/fda-approves-first-pembrolizumab-biosimilar
[3]: https://www.drugpatentwatch.com/p/tradename/KEYTRUDA
[4]: https://www.internationaldrugpriceindicator.org
[5]: https://www.cms.gov/inflation-reduction-act-and-medicare